Oral cavity (OC), oral pharyngeal (OP), and salivary gland (SG) cancer could possibly be the most expensive cancers to treat in the country today.
The finding comes from Delta Dental of Michigan’s Research and Data Institute (RDI) and involved the participation of Delta Dental of Wisconsin, Vanderbilt University and The University of Illinois at Chicago College of Dentistry. Chief Science Officer at Delta Dental, Dr. Jed Jacobson was a lead contributor to the study. The study commeneced in March of 2010 and its results will be published in BioMed Central’s open access journal, Head and Neck Oncology.
Utilizing Delta Dental’s RDI as well as a commercial price database the study analyzed the past claims of 6,812 OC/OP/SG patients with either Medicare of Medicaid benefits or with an employer-sponsored health plan.